MET and non-small cell lung carcinoma: In addition to NSCLC, research has indicated that the activation of the HGF/c-MET pathway is associated with increased PD-L1 expression in hepatocellular carcinoma following cisplatin treatment, downstream of the PI3K/Akt and MET/ERK pathways [190].